PDF herunterladen
CC BY-NC-ND 4.0 · AJP Rep 2017; 07(04): e205-e210
DOI: 10.1055/s-0037-1607028
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Anti-M Alloimmunization: Management and Outcome at a Single Institution

Bethany Stetson
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
,
Scott Scrape
2   Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio
,
Kara Beth Markham
1   Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, Ohio
› Institutsangaben
Weitere Informationen

Publikationsverlauf

02. Mai 2017

15. August 2017

Publikationsdatum:
22. November 2017 (online)

   Lizenzen und Reprints

Abstract

Objective The objective of this study was to review the management strategies and outcomes in gravidas with anti-M alloimmunization over 15 years.

Study Design Data collected from 195 pregnant patients with anti-M antibodies from July 2000 through June 2016 were reviewed retrospectively. We analyzed indirect antiglobulin test titer results, paternal or fetal/neonatal M antigen status, antepartum course, and perinatal outcomes.

Results Anti-M antibodies were found in 146 women and 195pregnancies. Among those with positive indirect antiglobulin tests, 193 pregnancies had titers at or below 1:4. Only one patient with an initial low titer experienced a more than twofold increase to a titer 1:64. Two women underwent an amniocentesis and cordocentesis. Ninety-five (73.6%) of the 129 infants tested were positive for the M antigen. Nine infants required phototherapy. There were no cases of hemolytic disease of the fetus or newborn, mild or severe.

Conclusion The incidence of severe hemolytic disease of the newborn due to anti-M is extremely low. We found no cases in our review of 195 pregnancies, despite several cases of severe hemolytic disease of the newborn reported in the literature. We have created an algorithm for the management of anti-M antibodies in pregnancy based on our data and extensive literature review.

Keywords

alloimmunization - anti-M - antibody - hemolytic disease of the fetus and newborn

Note

This study was approved by IRB 2015H0436 and was presented as poster presentation #192 at the 37th Annual Society for Maternal Fetal Medicine Meeting on January 26, 2017, in Las Vegas, NV.


 

  • References

  • 1 Moise Jr KJ, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012; 120 (05) 1132-1139
    CrossrefPubMedGoogle Scholar
  • 2 Koelewijn JM, Vrijkotte TG, van der Schoot CE, Bonsel GJ, de Haas M. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands. Transfusion 2008; 48 (05) 941-952
    CrossrefPubMedGoogle Scholar
  • 3 Klein HG, Anstee DJ. Mollison's Blood Transfusion in Clinical Medicine, 12 ed. Chichester, West Sussex, United Kingdom: John Wiley and Sons, Inc.; 2014
    Google Scholar
  • 4 Wikman A, Edner A, Gryfelt G, Jonsson B, Henter JI. Fetal hemolytic anemia and intrauterine death caused by anti-M immunization. Transfusion 2007; 47 (05) 911-917
    CrossrefPubMedGoogle Scholar
  • 5 Seo MW, Won HS, Kim SK. , et al. Successful treatment of fetal erythroblastosis due to anti-M alloimmunization with fetal intravascular transfusion. Prenat Diagn 2007; 27 (04) 385-387
    CrossrefPubMedGoogle Scholar
  • 6 Furukawa K, Nakajima T, Kogure T. , et al. Example of a woman with multiple intrauterine deaths due to anti-M who delivered a live child after plasmapheresis. Exp Clin Immunogenet 1993; 10 (03) 161-167
    PubMedGoogle Scholar
  • 7 Bajpayee A, Dubey A, Sonker A, Chaudhary RK. A case of severe foetal anaemia due to anti-M isoimmunisation salvaged by intrauterine transfusions. Blood Transfus 2014; 12 (Suppl. 01) s302-s304
    PubMedGoogle Scholar
  • 8 Kanra T, Yüce K, Ozcebe IU. Hydrops fetalis and intrauterine deaths due to anti-M. Acta Obstet Gynecol Scand 1996; 75 (04) 415-417
    CrossrefPubMedGoogle Scholar
  • 9 Matsumoto H, Tamaki Y, Sato S, Shibata K. A case of hemolytic disease of the newborn caused by anti-M: serological study of maternal blood. Acta Obstet Gynaecol Jpn 1981; 33 (04) 525-528
    PubMedGoogle Scholar
  • 10 MacPherson CR, Christiansen MJ, Newton Jr WA, Wheeler WE, Zartman ER. Anti-M antibody as a cause of intrauterine death. Report of two stillbirths resulting from anti-M antibody. Am J Clin Pathol 1961; 35: 31-35
    CrossrefPubMedGoogle Scholar
  • 11 Stone B, Marsh WL. Haemolytic disease of the newborn caused by anti-M. Br J Haematol 1959; 5: 344-347
    CrossrefPubMedGoogle Scholar
  • 12 Lin TH, Shih JC, Lin CH, Lin SY, Su YN, Lee CN. Intraperitoneal and intracardiac transfusion of recurrent fetal erythroblastosis due to anti-M alloimmunization with unfavorable outcome. Taiwan J Obstet Gynecol 2012; 51 (02) 253-255
    CrossrefPubMedGoogle Scholar
  • 13 Fung MK, Grossman BJ, Hillyer CD, Westhof CM. Core Principles in Cellular Therapy, 18th ed. Bethesda, MD: AABB; 2014. :viii, 96
    Google Scholar
  • 14 Mari G, Deter RL, Carpenter RL. , et al; Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med 2000; 342 (01) 9-14
    CrossrefPubMedGoogle Scholar
  • 15 De Young-Owens A, Kennedy M, Rose RL, Boyle J, O'Shaughnessy R. Anti-M isoimmunization: management and outcome at the Ohio State University from 1969 to 1995. Obstet Gynecol 1997; 90 (06) 962-966
    CrossrefPubMedGoogle Scholar
  • 16 Yasuda H, Ohto H, Nollet KE. , et al. Hemolytic disease of the fetus and newborn with late-onset anemia due to anti-M: a case report and review of the Japanese literature. Transfus Med Rev 2014; 28 (01) 1-6
    CrossrefPubMedGoogle Scholar
  • 17 Arora S, Doda V, Maria A, Kotwal U, Goyal S. Maternal anti-M induced hemolytic disease of newborn followed by prolonged anemia in newborn twins. Asian J Transfus Sci 2015; 9 (01) 98-101
    CrossrefPubMedGoogle Scholar
  • 18 Freiesleben E, Jensen KG. Haemolytic disease of the newborn caused by anti-M. The value of the direct conglutination test. Vox Sang 1961; 6: 328-335
    CrossrefPubMedGoogle Scholar
  • 19 Duguid JK, Bromilow IM. Haemolytic disease of the newborn due to anti-k. Vox Sang 1990; 58 (01) 69
    CrossrefPubMedGoogle Scholar
  • 20 Thompson DJ, Stults DZ, Daniel SJ. Anti-M antibody in pregnancy. Obstet Gynecol Surv 1989; 44 (09) 637-641
    CrossrefPubMedGoogle Scholar
  • 21 Hinchliffe RF, Nolan B, Vora AJ, Stamps R. Neonatal pure red cell aplasia due to anti-M. Arch Dis Child Fetal Neonatal Ed 2006; 91 (06) F467-F468
    PubMedGoogle Scholar
  • 22 Ishida A, Ohto H, Yasuda H. , et al. Anti-M antibody induced prolonged anemia following hemolytic disease of the newborn due to erythropoietic suppression in 2 siblings. J Pediatr Hematol Oncol 2015; 37 (06) e375-e377
    CrossrefPubMedGoogle Scholar
  • 23 Sharma D, Murki A, Murki S, Pratap T. Anti-M antibodies as a cause of intrauterine fetal death and neonatal hyperbilirubinaemia. BMJ Case Rep 2014; 2014 (14) bcr2014203534
    PubMedGoogle Scholar
  • 24 Kanra T, Erdem G, Tekinalp G, Gürgey A, Yigit S, Dogru D. Further hemolytic disease of the newborn caused by anti-M. Am J Hematol 1996; 53 (04) 280-281
    CrossrefPubMedGoogle Scholar
  • 25 Yoshida H, Yoshida Y, Konishi Y, Iwai Y, Asoh T, Tatsumi K. Hemolytic disease of the newborn due to anti-M. Nippon Ketsueki Gakkai Zasshi 1984; 47 (04) 888-895
    PubMedGoogle Scholar
  • 26 Duro EA, Desalvo L, Kuret S. Severe hemolytic disease of the newborn caused by anti-m antibodies. Iran J Pediatr 2013; 23 (05) 607-608
    PubMedGoogle Scholar
  • 27 Gagliardo FJ, Curiano RR. A rare form of anti-M antibody associated with pregnancy. Tech Bull Regist Med Technol 1963; 33: 198-200
    PubMedGoogle Scholar
  • 28 Melartin L, Kaarsalo E. Anti-M antibody developed during pregnancy. Scand J Haematol 1965; 2 (03) 183-186
    PubMedGoogle Scholar
  • 29 Bowman JM. Treatment options for the fetus with alloimmune hemolytic disease. Transfus Med Rev 1990; 4 (03) 191-207
    CrossrefPubMedGoogle Scholar
  • 30 Bowley CC, Dunsford I. The agglutinin anti-M associated with pregnancy; report on two cases. Br Med J 1949; 2 (4629): 681
    CrossrefPubMedGoogle Scholar
  • 31 Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology 2013; 29 (04) 127-130
    PubMedGoogle Scholar
  • 32 Mari G, Norton ME, Stone J. , et al; Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management. Am J Obstet Gynecol 2015; 212 (06) 697-710
    CrossrefPubMedGoogle Scholar